Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  Breaking News: FDA Approves Triumeq, New Once-Daily Combination Pill
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

FDA Application Is Submitted for Evaluating HIV Treatment

January 13, 2004

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Gilead Sciences Inc. has submitted an investigational new-drug application to the Food and Drug Administration to evaluate GS 9005, a potential protease inhibitor therapy that could be taken once daily. The drug's creator said GS 9005 might have a resistance profile that is distinct from commercially available drugs in the protease inhibitor class. Gilead plans to test the drug in healthy volunteers as well as HIV-positive patients. As an experimental drug, GS 9005 has not been determined to be safe or effective in humans for its intended use, Gilead said.

Back to other news for January 13, 2004

Adapted from:
Wall Street Journal
01.13.04

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More on HIV Medications
More on Protease Inhibitors in Development

Tools
 

Advertisement